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ABSTRACT 
Objective: This present study aims to produce cocrystal of paracetamol (PCA)-dipicolinic acid (DPA) using supercritical antisolvent (SAS) 
cocrystallization process in order to improve tabletability profile of PCA. 
Methods: The PCA-DPA cocrystal prepared by SAS cocrystallization were compared to those produced using a traditional solvent evaporation. The 
cocrystals produced were characterized using Powder X-Ray Diffraction (PXRD), Differential Scanning Calorimetry (DSC), Thermogravimetric 
Analysis (TGA), Polarized Light Microscopy (PLM), Fourier Transform Infrared (FTIR) spectroscopy, particle size analysis, Scanning Electron 
Microscopy (SEM) and High Performance Liquid Chromatography (HPLC). Analysis of flowability, drug content, solubility, dissolution, stability and 
powder compaction were performed to evaluate the cocrystals. 
Results: Cocrystal particles with mean diameter of 4.18 µm were produced from SAS process, smaller than those produced by traditional solvent 
evaporation method (mean diameter of 64.93 μm). The PCA-DPA cocrystal from SAS process showed an enhanced dissolution rate by 2.45 times 
compared to PCA, higher than cocrystal from traditional solvent evaporation (enhanced dissolution rate by 1.72 times compared to PCA). 
Tabletability study revealed superior tableting performance of both cocrystals compared to PCA. 
Conclusion: This study showed the utility of PCA-DPA cocrystal to improve mechanical properties of PCA while also demonstrating that 
simultaneous micronization and cocrystallization process can be obtained using SAS process. 
Keywords: Paracetamol, Dipicolinic acid, Cocrystal, Supercritical antisolvent, Tabletability, Micronization. 
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INTRODUCTION 
During the past few years, interest in cocrystals research has 
increased significantly in several areas, including in pharmaceutical 
sector. Cocrystallization, one of the emerging crystal engineering 
techniques is a potential means for improving water solubility [1], 
which is a well-known obstacle in the drug development process. 
Apart from potential improvement in the solubility aspect, 
pharmaceutical cocrystals were also frequently used to enhance 
other essential physicochemical properties of the API such as 
chemical stability [2], hygroscopicity [3], dissolution rate [4], 
mechanical properties [5] and bioavailability [6] without interfering 
the pharmacological activity of the API. In addition, cocrystal 
formation also provides the opportunities for pharmaceutical 
industry to create the intellectual property and new patents of API 
for extending their life cycle [7]. A cocrystal can be defined as 
crystalline complexes consisting of multiple neutral components 
which are solid under ambient conditions. The components in a 
cocrystal exist in a definite stoichiometric ratio, which interact 
together in the crystal lattice through noncovalent interactions such 
as hydrogen bonds, π-π stacking and van der Waals interactions [8]. 
Pharmaceutical cocrystals have been produced using several 
methods such as mechanochemical (eg. neat and solvent drop or 
liquid-assisted grinding) [9-10] or by solution crystallization 
approaches (eg. solvent evaporation techniques, slurry techniques, 
cooling, anti-solvent addition and reaction crystallization methods) 
[11-13]. Other cocrystal screening methods such as using thermal 
microscopy, hot stage microscopy (Kofler technique) [14] and 
Differential Scanning Calorimetry (DSC) [15] have also been 
reported. However, all of these technologies possess several 
problems that should be considered in cocrystal scaling up and 
production scale. Recently, several attempts have been conducted to 
produce cocrystals using several processes that were suitable for 
production scaling up, for example preparation of ibuprofen-
nicotinamide cocrystal has been performed using hot melt extrusion 
[16]. However, hot melt extrusion process confers the risk of 
thermal degradation of the components due to high temperature 
used. Alhalaweh and Velaga [17] also conducted spray drying 
process to obtain cocrystals. This process has been successful in 
obtaining pure cocrystals from solutions under incongruent 
conditions which cannot be obtained from slow evaporation 
process. However, this method also shows its limitation that it 
produced amorphous product due to its rapid solidification during 
the process. In addition to several methods described above, a new 
approach using supercritical fluid (SCF) technology for 
Cocrystallization process has also been conducted successfully. 
Carbon dioxide (CO2) at supercritical conditions is mainly used due 
to its relatively low critical temperature (31.1o
During the past years, the application of SCF especially supercritical 
CO
C) and pressure (73.8 
bar), nontoxic, nonflammable and inexpensive [18].  
2 in the pharmaceutical particle design field has been widely 
studied. Several different processes based on dense CO2 
precipitation techniques and their modifications have been 
investigated such as rapid expansion of supercritical solutions 
(RESS), particles from gas-saturated solutions (PGSS), supercritical 
anti solvent (SAS), solution enhanced dispersion by supercritical 
fluids (SEDS), depressurization of an expanded liquid organic 
solvent (DELOS), and supercritical assisted atomization (SAA) [19]. 
Recent reports [20-26] presented feasibility studies for the 
production of pharmaceutical cocrystals using SCF techniques. 
Padrela et al. [20] have shown that indomethacin-saccharin 
cocrystal was produced in different morphologies and sizes either 
by SAS or supercritical enhanced atomization (SEA) technique. The 
same author also used SEA technique to screen various cocrystals of 
several APIs [21-22]. Batch gas anti-solvent (GAS) was also used for 
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the formation of itraconazole-succinic acid, itraconazole-l-malic acid 
cocrystals and also for naproxen-nicotinamide cocrystal [23-25]. 
RESS process has also been used to produce ibuprofen-nicotinamide 
cocrystal [26]. 
SAS technique is a single step process for Cocrystallization and 
micronization simultaneously. This process is suitable for 
compounds that have low solubility in SCF. In this process, a solution 
of an organic solvent is pumped through a nozzle into a chamber 
simultaneously with a SCF, which act as anti-solvent. The particles 
are generated due to the supersaturation of the solute within the 
solution droplet [27]. In this study, SAS process was used to produce 
pharmaceutical cocrystals between paracetamol (PCA) as the drug 
and dipicolinic acid (DPA) as the coformer. The resulting cocrystal 
was analyzed and compared with cocrystal from traditional solvent 
evaporation process. The SAS process previously showed its ability 
to produce submicron size of cocrystals [20]. In addition, PCA 
micronization using SAS has already been studied by several 
researchers [27-29]. 
PCA is a widely used analgesic and antipyretic drug that is 
commonly used for relieving fever, headaches and other minor 
aches and pains [30]. PCA is one of the most studied API for its solid 
form modification, i. e Cocrystallization and salt formation. From a 
crystal engineering viewpoint, PCA is a good API model for cocrystal 
design. As shown in fig. 1, PCA contains several functional groups, i. 
e amide and hydroxyl groups, which can act as donor and acceptor 
in hydrogen-bonding [31]. DPA (fig. 1) contains two carboxylic acid 
groups and one pyridine group that can act as a hydrogen bond 
donor and acceptor. Cocrystallization experiment of PCA and 
coformer 2,4-pyridinedicarboxylic acid which has similar structure 
to DPA has been investigated [32]. Solid-state material 
characterization techniques such as powder X-ray diffraction 
(PXRD), differential scanning calorimetry (DSC), fourier transform 
infrared (FTIR) spectroscopy, laser diffractometry (LD) analysis, 
polarized light microscopy (PLM) and scanning electron microscopy 
(SEM) were performed for PCA-DPA cocrystal characterization. 
Their solubility, dissolution rate, stability and tabletability studies 
were also investigated. 
 
Fig. 1: Chemical structure of paracetamol (PCA) and Dipicolinic 
acid (DPA) 
MATERIALS AND METHODS 
Materials 
Paracetamol was purchased from Zhejiang Kangle Pharmaceutical 
Co., Ltd. (Wenzhou, China). Dipicolinic acid (DPA) was obtained from 
Sigma-Aldrich, Co. (MO, USA). Methanol (ACS grade), potassium 
dihydrogen phosphate (KH2PO4) and sodium hydroxide (NaOH) 
were obtained from Merck KGaA (Darmstadt, Germany). Acetonitrile 
(HPLC grade) was obtained from J. T. Baker, Inc. (NJ, USA). High 
purity of carbon dioxide (CO2
Experimental procedures 
, purity of 99.95%) was purchased 
from PT Intergas (Jakarta, Indonesia). Polytetrafluoroethylene 
(PTFE) membrane with a size of 0.22 μm was purchased from 
Fioroni Filters (Ingre, France). 
Cocrystallization by rapid evaporation process 
Equimolar (1:1 mol ratio) quantities of PCA and DPA were dissolved 
in 20 ml of methanol and mixed under sonication at 40 °C for 10 
min. The resulting solution was then placed into crystallizing disk 
and heated at 70 °C for 5 h using hot plate to evaporate the solvent. 
The dried solid was collected and placed in the glass vial for further 
analysis. The cocrystal product from this experiment was further 
namely as PCA-DPA-RE. 
SAS cocrystallization apparatus 
Cocrystallization was conducted using a custom-built supercritical 
anti-solvent (SAS) apparatus as shown in fig. 2. Solution reservoir 
(9) was a 110 ml Pyrex dropping funnel. High-pressure pump for 
CO2 (3) was a Thar P-50 pump (Thar Technology, PA, USA). High-
pressure pump for solution (8) was a Lab Alliance 1200 series (Lab 
Alliance, PA, USA). The precipitation chamber (7) was made of 
stainless steel 316 (SS316) with 100 ml internal volume and water 
jacket to control the temperature of precipitator. To observe the 
process of particle formation, a pair of glass windows was installed 
in front and back side of the precipitation chamber. A stainless steel 
capillary tube with internal diameter of 2.54 x 10-4 m was used as a 
nozzle and it was placed on the top of precipitation chamber. The 
CO2 precooler (2) and preheater (6) were a shell and tube type. The 
inner tube was a coiled tube with 0.6 m length and 3.175 x 10-3 m 
outside diameter that made of SS316. The shell was made from 
SS316 with 0.11 in diameter and 0.25 m length. The products were 
filtered using 0.22 µm polytetrafluoroethylene (PTFE) membrane 
filter (10). Pressure of the precipitation chamber was controlled 
using a model 26-1721-24 back pressure regulator (11), 
manufactured by Tescom, Co. (MN, USA). The precooler and CO2
 
 
pump temperature was maintained using cooling circulator (4).
 
Fig. 2: Schematic diagram of custom-built SAS apparatus (1) CO2 cylinder, (2) precooler, (3) high-pressure pump for CO2, (4) cooling bath, 
(5) heating bath, (6) preheater, (7) precipitation chamber, (8) high-pressure pump for solution, (9) solution reservoir, (10) filter, (11) 
back pressure regulator, (12) separator 
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SAS Cocrystallization 
Equimolar (1:1 mol ratio) quantities of PCA and DPA were dissolved 
in 20 ml of methanol and mixed under sonication at 40 °C for 10 min 
to obtain clear solution. The Cocrystallization started by supplying 
fresh CO2 into precipitation chamber. After stable pressure (100 
bar) and temperature (40 °C) were achieved, solution was sprayed 
into precipitation chamber at flow rate of 1 ml/min. At the same 
time, CO2 was also pumped into the precipitation chamber at CO2 
flow rate of 30 g/min. After all solution was sprayed, CO2
Characterization of cocrystal 
 was 
supplied continuously for 30 min to remove all remaining solvent in 
the product inside the precipitation chamber and filter. Products 
were collected from the filter after depressurizing the precipitation 
chamber. The co crystal product from this experiment was further 
namely as PCA-DPA-SAS. 
Powder x-ray diffraction (PXRD)  
Powder X-Ray Diffraction (PXRD) patterns were collected by a 
Rigaku Ultima IV X-ray diffractometer (Rigaku Co., Tokyo, Japan) 
using Cu Kα radiation (λ = 1.54 Å), a tube voltage of 40 kV and a tube 
current of 40 mA. Data were collected from 2 to 40 ° at continuous 
scan rate of 4 °/min. 
Differential scanning calorimetry (DSC) 
Thermal analysis of the samples was performed using DSC on a DSC 
Q20 (TA Instruments, DE, USA) which was calibrated for 
temperature and cell constants using indium. Samples (1-3 mg) 
crimped in aluminum pan were analyzed from 50 to 300 °C with 
heating rate of 10 °C/min. Samples were continuously purged with 
nitrogen at 50 ml/min. 
Thermogravimetric analysis (TGA) 
Thermogravimetric Analysis (TGA) was performed on a TGA Q50 
(TA Instruments, DE, USA) instrument. Approximately 1-5 mg 
sample was heated from 50 to 300 °C in open aluminium pan at rate 
of 10 °C/min under nitrogen purge at flow rate of 50 ml/min. 
Polarized light microscopy (PLM) 
All Polarized Light Microscopy (PLM) experiments were performed 
using BX-50 polarizing microscope (Olympus, Tokyo, Japan). 
Photomicrographs were captured using Olympus SC-30 digital color 
camera and analyzed using Analysis getIT software. 
Fourier transform infrared (FTIR) spectroscopy 
IR spectra of the compounds were recorded on a FT/IR-6100 type A 
infrared spectrometer (JASCO, MD, USA) in ATR mode from 4000-
700 cm−1 with a resolution of 4 cm−1
Particle size analysis 
. 
Particle size was determined by laser diffractometer (Mastersizer 
2000, Malvern Instruments, USA) using the dry powder dispersing 
system Scirocco 2000 at pressure of 2 bar. Particle size was 
characterized by volume-weighted mean diameter D [4,3]. The 
particle size results represent average values over three 
measurements performed on each sample. 
Scanning electron microscopy (SEM) 
The morphology of the samples was analyzed using a JEOL JSM-6510 
scanning electron microscopy (SEM, JEOL Ltd. Tokyo, Japan). 
Samples were mounted on a double-faced adhesive tape, sputtered 
with platinum. Scanning electron photographs were taken at an 
accelerating voltage of 5 kV. 
High performance liquid chromatography (HPLC) 
The concentrations of PCA in solutions was determined using High 
Performance Liquid Chromatography (HPLC) by Waters Alliance 
HPLC system which includes a Waters e2695 separation module, a 
Waters 2489 UV detector and a 4.6 mm×250 mm Sun Fire C18 with 
5 μm column (Waters Corporation, Milford, MA). The mobile phase 
consisted of methanol and water (65/35, %v/v), with a flow rate of 
1.0 ml/min. PCA was detected at 243 nm. The injection volume was 
20 µl. Data acquisition and analysis was performed using software 
Empower 2.0. 
Evaluation of cocrystal 
Flowability analysis 
Flow properties of PCA and cocrystals were determined in terms of 
Carr's Index and Hausner ratio. Bulk and tapped densities were 
measured in order to calculate Carr's Index and Hausner ratio. 
Hausner ratio was calculated from ratio of tapped density to bulk 
density, whereas Carr's Index was calculated according to the 
following equation:  
Carr’s index = [(tapped density-bulk density)/tapped density] x100.  
The measurement of bulk and tapped density was done triplicate. 
Drug content analysis 
Accurately weighed amount of cocrystal was dissolved in methanol. 
The solution was then filtered through 0.22 µm PTFE syringe filter 
(Whatman, USA). PCA content was determined using HPLC (n = 3). 
Solubility measurement 
Excess amounts (500 mg) of the samples were suspended in 20 ml 
of phosphate buffer pH 5.8 in screw-capped glass vials and the 
suspension was stirred using a magnetic stirrer at 25 °C. After 24 h, 
the suspension was filtered through a paper filter; solid filtrate was 
dried and used for further PXRD analysis. The resulting solution was 
filtered again through a 0.22 μm nylon syringe filter (Whatman, 
USA). The filtered aliquot was sufficiently diluted. A concentration of 
PCA in solution was determined using HPLC. 
In vitro dissolution study 
To minimize the size effect on dissolution results, PCA and PCA-DPA-
RE were sieved through 60-mesh sieves (mesh size 250 µm). 
Dissolution rate studies of the PCA, PCA-DPA-RE and PCA-DPA-SAS 
were performed in DT-700 dissolution apparatus (Erweka, 
Germany) according to the USP paddle method [33]. The experiment 
was conducted in 900 ml phosphate buffer solution pH 5.8. The 
temperature of the dissolution medium was kept at 37 °C and speed 
of the agitator was at 50 rpm. A specific amount of samples 
(equivalent to 500 mg of PCA) was added into the dissolution 
medium. At specific time intervals, 5 ml solution was withdrawn and 
concentration of PCA was determined using HPLC. 
Stability study 
Stability study was done by placing accurately weighed samples 
(approximately 100 mg) in 10 ml capped (closed condition) and 
uncapped glass vials (open condition). Both glass vials were 
placed into a stability chamber (Type KBF 720, Binder, Germany) at 
40 °C/75% RH for one month, then the samples were analyzed by 
PXRD. 
Powder compaction study 
Evaluation of cocrystal was also performed by powder compaction 
analysis. In order to minimize the size difference between PCA and 
PCA-DPA-RE, both samples were sieved through 60-mesh sieves 
(mesh size 250 µm). Approximately 500 mg of powder was manually 
filled into a tableting die and compressed at pressures of 4.9-29.4 kN 
using hydraulic press apparatus (Perkin Elmer, MA, USA). Tablets 
(13 mm diameter) were allowed to relax overnight before their 
diameter, thickness and hardness were measured. The diameter and 
thickness of tablets were measured using a thickness gauge 
(Mitutoyo, Japan) and the tablet hardness was tested using a 
hardness tester (Type PTB 111, Pharma Test, Germany). Maximum 
breaking force, tablet diameter and tablet thickness were used to 
calculate tensile strength according to Eq. 1. 
σ =  …… (1) 
Where σ is tensile strength (MPa), F is the breaking force (N), D is 
the tablet diameter (mm) and T is the thickness of tablet (mm). 
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Tabletability profiles were obtained by plotting tensile strength as a 
function of compaction pressure. 
RESULTS AND DISCUSSION 
Powder x-ray diffraction (PXRD) analysis 
PXRD is a useful method for identification of new crystalline phase 
from Cocrystallization experiments. Fig. 3d-e shows the PXRD 
patterns for the products from Cocrystallization process via rapid 
solvent evaporation and SAS Cocrystallization. The products 
obtained from each method have identical spectra. This result 
confirms that PCA-DPA cocrystal is successfully produced from SAS 
Cocrystallization experiment and it has similar internal crystal 
structure to PCA-DPA cocrystal from rapid solvent evaporation 
process. The diffractogram of PCA-DPA cocrystal was 
distinguishable from the individual compounds. It exhibited peaks at 
2θ values of 8.58 °, 9.46 °, 10.50 °, 12.56 °, 13.60 °, 17.24 °, 24.12 ° 
and 26.78 °. The different peaks in the PXRD pattern of cocrystal 
could imply the existence of interactions between PCA and DPA to 
form new cocrystalline phase. Fig. 3d-e also shows, although the 
diffraction peaks characteristics of PCA-DPA-RE and PCA-DPA-SAS 
cocrystal were observed at the same 2θ position, intensity of 
diffraction peaks were different at several 2θ positions. The 
difference of diffraction peaks intensity can be explained by 
preferred orientation. Preferred orientation is a condition in which 
the distribution of crystal orientation is nonrandom and a specific 
crystalline frame may tend to cluster to a greater or lesser degree 
about some particular orientation [34]. These results show that the 
crystallization condition may control the crystallinity of the product. 
 
Fig. 3: Powder X-ray diffractograms of (a) PCA, (b) DPA, (c) 
physical mixture of PCA: DPA (1:1 mol ratio), (d) PCA-DPA-RE 
and (e) PCA-DPA-SAS 
 
Thermal analysis 
DSC and TGA experiments were carried out to study the thermal 
behavior of PCA-DPA cocrystal. The DSC thermograph for PCA, DPA, 
physical mixture of PCA and DPA in 1:1 mol ratio (PM), PCA-DPA-RE 
and PCA-DPA-SAS were given in fig. 4. It shows that PCA exhibited a 
melting endothermic peak at 170.23 °C, while DPA showed melting 
endothermic at 251.74 °C. DSC analysis for the physical mixture of 
PCA and DPA (1:1 mol ratio) showed two endothermic peaks (first 
endothermic peak at 164.82 °C, which could be attributed to the 
eutectic temperature of the mixture followed by second melting 
endotherm at 190.10 °C, which indicates the melting point of 
cocrystal). This observation was in accordance with the report from 
Lu et al., 2008 [35], who demonstrated the use of DSC in cocrystal 
screening. They explained that formation of cocrystal could be 
predicted if there were two endothermic peaks (corresponding to 
eutectic mixture and cocrystal melting) obtained during the physical 
mixture melting process in DSC analysis [36-37]. DSC analysis of the 
products from cocrystallization experiments shows single 
endothermic peak which lies between the melting points of the 
parent compounds (PCA and DPA). PCA-DPA-RE and PCA-DPA-SAS 
exhibited endothermic melting point at 193.57 °C and 194.13 °C 
followed by broad endothermic peak corresponding to the 
decomposition of the cocrystals. This shift in the cocrystal’s melting 
point compared to the parent compounds might be due to the 
interaction (hydrogen bonding interaction) between API and 
coformer, resulted in different packing arrangement or change in the 
crystal lattice [38]. The single melting event of the cocrystals and no 
parent compound melting event in the thermograms of the 
cocrystals also indicate that there were no uncocrystallized parent 
compounds in the final product. A distinct cocrystal melting point in 
between the parent compound’s melting point is in agreement with 
previous reports in the literature for a number of cocrystals. 
Schultheiss and Newman [8] conducted a survey on melting points 
of 50 reported cocrystalline samples and found that half of 
cocrystals had melting points between the pure components. The 
enthalpy of fusion (∆H) of PCA-DPA-RE and PCA-DPA-SAS were 
156.2 and 119.7 J/g, respectively. This result showed that cocrystal 
from SAS Cocrystallization process has lower enthalpy of fusion. 
This lower enthalpy of fusion in PCA-DPA cocrystal from SAS 
process might be due to the reduction of particle size after SAS 
process [18].  
 
 
Fig. 4: DSC thermograms of (a) PCA, (b) DPA, (c) physical 
mixture of PCA: DPA (1:1 mol ratio), (d) PCA-DPA-RE and (e) 
PCA-DPA-SAS 
 
TGA was conducted to analyze the changes in cocrystal weight in 
relation to the change of temperature (fig. 5). TGA curve showed no 
weight loss until melting suggesting that the PCA-DPA-RE and PCA-
DPA-SAS cocrystals were not solvate or not hydrate. TGA of these 
cocrystals showed that there was mass loss after melting points, 
which attributed to the degradation of cocrystals. 
 
 
Fig. 5: TGA thermograms of (a) PCA, (b) DPA, (c) PCA-DPA-RE, 
and (d) PCA-DPA-SAS 
 
Temperature-composition phase diagrams of PCA-DPA were 
constructed based on DSC experiments for binary mixtures of 
cocrystal formers at various molar compositions (fig. 6). This 
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diagram confirms that PCA-DPA cocrystal was an incongruent 
system [39], in which eutectic melting point occurred at ~164 °C 
and cocrystal melting point (peritectic point) occurred at ~190 °C. 
 
 
Fig. 6: Melting point phase diagram of PCA-DPA cocrystal 
system 
 
Polarized light microscopy (PLM) images 
The PLM photomicrographs of PCA, DPA and physical mixture of 
PCA and DPA (1:1 mol ratio) after recrystallized from methanol are 
shown in fig. 7a-c. The product from recrystallization of physical 
mixture of PCA and DPA (at 1:1 mol ratio) using methanol has a 
different crystal habit compared to its starting components. Thus it 
confirms the interaction between PCA and DPA to form new solid 
phase (cocrystal) which has different crystal habit. The crystal habit 
of a drug is an important variable in pharmaceutical manufacturing. 
The changes in the crystal habit of raw material after 
cocrystallization can influence its physicomechanical properties and 
it affects the performance of dosage form [40]. 
Fourier transform infrared (FTIR) spectroscopy analysis 
FTIR spectroscopy can be used to confirm the formation of cocrystal. 
The changes in vibrational frequencies of the functional groups can 
be directly correlated with the changes in hydrogen bonding due to 
formation of cocrystal [41]. From the chemical structures of PCA and 
DPA (fig. 1), there are several functional groups which are able to 
form intermolecular hydrogen bonding, thus several possible 
synthon to form can be obtained. The FTIR spectra of PCA, DPA, 
PCA-DPA-RE and PCA-DPA-SAS cocrystal are shown in fig. 8. Table 1 
shows the list of relevant IR bands for PCA, DPA and all cocrystals 
[42]. The results reveal the changes in the IR bands of the cocrystals 
compared to the pure components, indicating the presence of 
intermolecular hydrogen bonding. 
The new bands at ~3300 cm−1 in the PCA-DPA cocrystal can be 
assigned to the intermolecular hydrogen bond interaction O∙∙∙N-H 
between C=O (carbonyl functional group) in the DPA and N−H 
(amide functional group) in the PCA. The O–H stretch of DPA 
occurred at 3066.82 cm−1 for the pure coformer. The frequency of 
this stretch shifted into higher wavenumber (~3110-3200 cm−1
The FTIR analysis also can be used to determine whether proton 
transfer from carboxylic acid had occurred, which can differentiate 
the formed product between salt and cocrystal. In the formation of a 
salt species, there were typical carboxylate anions which have two 
carbonyl stretching bands: a strong asymmetrical band below 1600 
cm
) in 
the PCA-DPA cocrystals prepared by each method. The transition of 
O–H stretch of DPA suggests that this group also participates in a 
hydrogen bond in the cocrystal product. Based on the changes in the 
frequency of these functional groups, we hypothesized the formation 
of cocrystal between PCA and DPA via heterosynthon formation 
between carboxylic acid (from DPA functional group) and amide 
groups (from PCA functional group) [43-44].  
-1 and a weaker symmetrical band near 1400 cm-1. On the other 
hand, when the frequency of carbonyl group in carboxylic acid 
shifted to the higher energy (approximate frequency range of 1700-
1730 cm-1), a cocrystal species had formed [45]. Fig. 8c-d shows 
carbonyl functional group in PCA-DPA cocrystal shift into higher 
frequency of ~1720-1730 cm-1
 
. Therefore, proton transfer does not 
occur between PCA and DPA and thus confirms the cocrystal 
formation between PCA and DPA.
   
Fig. 7: Polarized light microscopy (PLM) images of (a) PCA, (b) DPA, (c) physical mixture of PCA: DPA (1:1 mol ratio) after recrystallized 
using methanol 
 
Table 1: Bond stretching frequencies in PCA, DPA, PCA-DPA-RE and PCA-DPA-SAS, determined from FTIR analysis 
Assignment PCA DPA PCA-DPA-RE PCA-DPA-SAS 
ν(N−H)/cm 3321.04 -1 - 3346.69 3345.26 















- 3300.69 3301.86 
PCA: Paracetamol, DPA: Dipicolinic acid, RE: Rapid evaporation, SAS: Supercrtical antisolvent. 
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Fig. 8: FTIR spectra of (a) PCA, (b) DPA, (c) PCA-DPA-RE and (d) 
PCA-DPA-SAS 
 
Flowability and particle size analysis 
Flowability of PCA and resulted cocrystals are shown in table 2. The 
calculated Carr’s index and Hausner ratio of PCA and cocrystals 
which represent flowability, showed that cocrystals have improved 
flowability compared to PCA. The improvement in flowability of 
PCA-DPA-RE could be due to the reduction of cohesiveness of the 
powder. Less irregular habit (fewer points for physical contact) of 
PCA-DPA-RE compared to PCA resulted in the reduction of 
interparticle contact areas and thus reducing cohesiveness of the 
powder, which can be confirmed by SEM picture. Similar 
observation was also found by another researcher [46]. Generally, 
particles with smaller size tend to be more cohesive and have poorer 
flowability compared to larger particle [38]. However, PCA-DPA-
SAS, which has smaller particle size of 4.18±0.054 µm, has better 
flowability than PCA which has larger particle size of 45.33±0.439 
µm. This could be attributed due to their more regular polyhedral 
crystal habit that improved the free flowing of the powder compared 
to PCA powder. PCA powder has larger size but it has a habit that led 
to higher contact area. On the other hand, slightly reduction in the 
flowability of PCA-DPA-SAS compared to that of PCA-DPA-RE 
(particle size of 64.93±0.095 µm) may be attributed to their smaller 
particle size. These findings show that the flowability of PCA-DPA 
cocrystal was preferably improved compared to pure PCA. Fig. 9 
shows that SAS process can produce PCA-DPA cocrystal with smaller 
average particle size and particle size distribution (fig. 9d). This 
result shows that SAS process was an efficient process to produce 
submicron size of PCA-DPA cocrystal. 
 
 
Fig. 9: Particle size distribution (PSD) profile of (a) PCA, (b) 
DPA, (c) PCA-DPA-RE and (d) PCA-DPA-SAS 
 
Scanning electron microscopy (SEM) analysis 
Morphology of the API has influenced various pharmaceutical 
parameters such as flowability, compaction, compressibility, 
solubility and dissolution characteristics of drug powder [16]. Fig. 
10 shows SEM micrographs of PCA, DPA and PCA-DPA cocrystals. 
PCA crystals exhibited an irregular rod-like or columnar habit (fig. 
10a). This is in accordance to previous report [46]. DPA crystal 
showed thin plate-like crystals (fig. 10b). Fig. 10c-d shows SEM 
micrographs of PCA-DPA-RE and PCA-DPA-SAS. PCA-DPA-RE 
cocrystal showed irregular rod-like crystals, whereas PCA-DPA-SAS 
cocrystal showed a different crystal habit. It showed a prismatic 
polyhedral crystals and smaller particle size compared to PCA-DPA-
RE. Differences in crystal habit obtained due to differences in the 
environmental conditions of crystal growth, which lead to the 
formation of crystals with different external shapes (crystal habit) 




Fig. 10: SEM images of (a) PCA, (b) DPA, (c) PCA-DPA-RE and (d) PCA-DPA-SAS 
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Table 2: Flow properties of PCA, PCA-DPA-RE and PCA-DPA-SAS 
Sample Carr’s index (%) Hausner Ratio Flow characteristic 
PCA 43.18±1.31 1.76±0.04 Very, very poor 
PCA-DPA-RE 22.27±1.17 1.29±0.02 Passable 
PCA-DPA-SAS 27.21±1.09 1.37±0.02 Poor 
PCA: Paracetamol, DPA: Dipicolinic acid, RE: Rapid evaporation, SAS: Supercrtical antisolvent 
 
Drug content analysis 
PCA content in PCA-DPA cocrystal was determined by HPLC. The 
percentage of PCA content in PCA-DPA-RE and PCA-DPA-SAS were 
44.98±0.77 and 41.83±0.66 (%), respectively. The calculated content 
of DPA was 53.91±2.991 and 58.17±0.66 (%) for PCA-DPA-RE and 
PCA-DPA-SAS. The molar ratio of PCA and DPA was determined to 
be 1:1 since the theoretical percentage of the two components are 
47.49% and 52.51%. The low PCA content in PCA-DPA-SAS might be 
due to the slight solubility of PCA in sCO2
Powder compaction analysis 
 during the process, which 
was confirmed by other researchers [48]. 
Fig. 11 shows the compaction pressure-tablet tensile strength 
profiles for PCA, DPA, PCA-DPA-RE and PCA-DPA-SAS cocrystal. 
Tabletability profile was determined over a compaction pressure 
range of 4.9 kN to 29.4 kN. The tablet tensile strength of PCA could 
not be measured at all compression pressures because the tablets 
capped immediately after being taken out from the die. Similar 
finding was also found by another researcher [49]. In contrast, DPA, 
PCA-DPA-RE and PCA-DPA-SAS exhibited much better tabletability 
as shown in fig. 11b-d. Tablet tensile strength has to reach 2 MPa to 
ensure the integrity of a pharmaceutical tablet [50]. This criteria was 
fulfilled by PCA-DPA-RE at >14.7 kN compaction pressure and >29.4 
kN compaction pressure for PCA-DPA-SAS. This result indicates 
better tabletability of PCA-DPA-RE compared to PCA-DPA-SAS. 
Generally for most powdered pharmaceuticals, compaction of 
smaller particles resulted stronger tablets because smaller particles 
provide larger total area for bonding than larger particles [51]. Due 
to the fact that PCA-DPA-SAS process had smaller particle size than 
PCA-DPA-RE, the tensile strength of tablets produced from PCA-
DPA-SAS should be higher than the tablet tensile strength of PCA-
DPA-RE. However, the tablets of PCA-DPA-SAS showed lower 
mechanical strength compared to the tablets of PCA-DPA-RE. It has 
been reported that poor compressibility of drug crystals can be 
attributed to the presence of crystal faces that give poor adhesion to 
other crystals and the absence of the faces that are required for 




Fig. 11: Tablet ability of (a) PCA, (b) PCA-DPA-SAS, (c) PCA-DPA-
RE, (d) DPA, and (e) overview of each tablet 
Here in this study,, for the more regular habit (polyhedral habit) of 
PCA-DPA-SAS led to lower contact area compared to irregular rod-
like crystal habit of PCA-DPA-RE. This can affect the inter-particulate 
bonding between these crystals, and resulting in different 
compression properties [53]. Better compression was observed for 
PCA-DPA-RE which has more irregular size (larger PSD) and habit 
(shape). In this case, uniform-sized PCA-DPA-SAS cocrystal might be 
difficult to orient in different direction, resulting in poor compaction. 
In contrast, PCA-DPA-RE cocrystal has different size and more 
irregular habit. Fines from this product could fill into cavities in 
between larger particles [54]. This resulted in better compaction 
behavior of PCA-DPA-RE compared to PCA-DPA-SAS. Differences in 
tableting properties of PCA-DPA-RE and PCA-DPA-SAS may also be 
attributed to the difference in their flow properties. Because of the 
better flowability of PCA-DPA-RE, the powder filled homogeneously 
into the die and the contact between crystals was more intensive. 
Therefore, the input of energy into the powder is much more 
effective, resulted in increased tensile strength of the tablet [55]. 
Dissolution test 
To verify whether formation of cocrystals could modify the 
dissolution behavior of PCA, the release of PCA from PCA-DPA-RE 
and PCA-DPA-SAS cocrystal was investigated via dissolution 
experiments and compared to PCA. The dissolution profiles of PCA, 
PCA-DPA-RE and PCA-DPA-SAS cocrystals are shown in fig. 12. It is 
shown that both PCA-DPA cocrystals exhibited improvement in 
dissolution rate compared to pure PCA. The improvement in 
dissolution of PCA-DPA-RE cocrystal compared to PCA might be due 
to reduction of powder cohesiveness. On the other side, 
improvement in dissolution of PCA-DPA-SAS co crystal compared to 
PCA is likely due to the significant reduction of particle size. Weibull 
equation and similarity factor were used to compare the dissolution 
profile between PCA and PCA-DPA cocrystal [18, 56]. The 
dissolution rate coefficient (kw) value obtained from Weibull 
equation of the PCA, PCA-DPA-RE and PCA-DPA-SAS were 0.118 
min-1, 0.202 min-1 and 0.289 min-1
 
. Based on this result, the 
dissolution rate of PCA-DPA-RE was enhanced approximately 1.72 
times compared to PCA and the dissolution rate of PCA-DPA-SAS 
was enhanced approximately 2.45 times compared to PCA. 
Furthermore, the different factor (f1) and similarity factor (f2) were 
used to analyze the dissolution profile.  
       ………….(2) 
………….(3) 
Where Rj and Tj are the cumulative percentage dissolved at each of 
selected n time points of the unprocessed particles (reference) and 
processed particles (test product), respectively. In general, the 
dissolution profiles were taken as similar with f1 value lower than 
15 and f2 value higher than 50. The comparison of dissolution 
profile using f2 has also been adopted by food and drug 
administration (FDA) and european medicines agency (EMEA) in the 
assessment of similarity between two dissolution profiles [18,56]. In 
this study, comparison between dissolution profile of PCA and PCA-
DPA-RE resulted in similarity for their dissolution profiles as 
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indicated by the difference and similarity factor (f1 and f2) value of 
11.06 and 53.51, respectively. On the other hand, comparison 
between dissolution profile of PCA and PCA-DPA-SAS resulted in 
difference for their dissolution profile as indicated by the difference 
and similarity factor (f1 and f2) value of 15.31 and 46.11, 
respectively. This result confirmed that the dissolution character of 








The solubility of PCA and PCA-DPA co crystal was determined at 24 
h in phosphate buffer pH 5.8. The results of solubility study show 
that the solubility values of PCA-DPA-RE and PCA-DPA-SAS 
cocrystals were 6297.5 ppm and 6277.5 ppm, respectively. Although 
this is lower than the solubility of PCA (14989.6 ppm), it does not 
cause any problem in the dissolution of this compound because 
more than 80% PCA has already been released (dissolved) in the 
dissolution medium in 30 min as required for its dissolution 
requirement [33]. The incorporation of less soluble conformer into 
the crystal lattice of cocrystals may reduce the solubility of PCA, as 
the aqueous solubility (25 °C) of DPA (5 mg/ml) is less than that of 
PCA (12.78 mg/ml). The effective arrangement of crystal packing in 
cocrystals via supra molecular interactions, such as hydrogen 
bonding, will also contribute to their reduced solubility. The solid 
residues obtained after the solubility studies were then characterized by 
PXRD. The PXRD patterns of PCA and PCA-DPA co crystal after solubility 
study (fig. 13) were found to be similar to that of their original forms 
indicating stability of these cocrystals in the solubility medium for 24 h.  
 
 
Fig. 13: Powder X-ray diffractograms before solubility study for 
(a) PCA, (b) DPA, (c) PCA-DPA-RE, (d) PCA-DPA-SAS and after 
solubility study in phosphate buffer pH 5.8 for (e) PCA, (f) DPA, 
(g) PCA-DPA-RE, (h) PCA-DPA-SAS 
Stability study 
PCA, PCA-DPA-RE and PCA-DPA-SAS cocrystals were kept under 
accelerated stability conditions of 40 °C/75% RH and analyzed by 
PXRD after 1 mo. The results of PXRD analysis demonstrate that the 
PXRD patterns of PCA, PCA-DPA-RE and PCA-DPA-SAS cocrystal did 
not change (fig. 14). This analysis indicates that PCA-DPA-RE and 
PCA-DPA-SAS cocrystal were physically stable under accelerated 
stability condition studied. 
 
Fig. 14: Powder X-ray diffractograms resulting from stability 
study under accelerated conditions (a) PCA day 0, (b) PCA day 
30 in open condition, (c) PCA day 30 in close condition, (d) PCA-
DPA-RE day 0, (e) PCA-DPA-RE day 30 in open condition, (f) PCA 
DPA-RE day 30 in close condition, (g) PCA-DPA-SAS day 0, (h) 
PCA-DPA-SAS day 30 in open condition, and (i) PCA-DPA-SAS 
day 30 in close condition 
 
CONCLUSION 
In this study, we show successful production of PCA and DPA 
cocrystal using SAS Cocrystallization and traditional rapid solvent 
evaporation process. The formation of new crystalline phases was 
confirmed from PXRD, DSC, FTIR, PLM and SEM analysis. The 
particle size of cocrystal particles produced by SAS was smaller than 
those produced by traditional rapid solvent evaporation process. 
Dissolution test of PCA-DPA cocrystal from SAS process shows 
significant enhancement in dissolution rate approximately 2.45 
times compared to PCA alone. The cocrystals were found to be stable 
over the period of 1 mo confirmed from stability studies. PCA-DPA 
cocrystals from SAS process and traditional rapid solvent 
evaporation process show remarkable enhancement in the tableting 
properties compared to PCA. This study demonstrates the ability of 
SAS process to produce submicron size of PCA-DPA cocrystal with 
altered physicochemical properties in a single step process.  
ACKNOWLEDGEMENT 
The authors acknowledge Dexa Laboratories of Biomolecular 
Sciences (DLBS)–PT. Dexa Medica for financial support. The authors 
would like to thank Karmelita Anggrianto, Isabela Anjani and 
Destrina Grace for critical review on this manuscript.  
ABBREVIATION 
API-Active Pharmaceutical Ingredient, CO2-Carbon dioxide, DELOS-
Depressurization of an Expanded Liquid Organic Solvent, DPA-
Dipicolinic acid, DSC-Differential Scanning Calorimetry, EMEA-
European Medicines Agency, FDA-Food and Drug Administration, 
FTIR-Fourier Transform Infrared Spectroscopy, GAS-Gas Anti-
solvent, HPLC-High Performance Liquid Chromatography, HSPM-Hot 
Stage Polarized Microscopy, IR-Infrared, KH2PO4-Potassium 
dihydrogen phosphate, LD-Laser diffraction, NaOH-Sodium 
hydroxide, PCA-Paracetamol, PGSS-Particles from Gas Saturated 
Solutions, PLM-Polarized Light Microscopy, PM-Physical Mixture, 
PTFE-Polytetrafluoroethylene, PXRD-Powder X-ray Diffraction, 
RESS-Rapid Expansion of Supercritical Solutions, RH-Relative 
Humidity, SAA-Supercritical Assisted Atomization, SAS-Supercritical 
Anti solvent, SCF-Supercritical Fluid, sCO2-Supercritical Carbon 
Dioxide, SEA-Supercritical Enhanced Atomization, SEDS-Solution 
Tjandrawinata et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 2, 89-98 
97 
Enhanced Dispersion by Supercritical fluids, SEM-Scanning Electron 
Microscope, TGA-Thermogravimetric Analysis. 
CONFLICT OF INTERESTS 
The authors declared no conflicts of interest with respect to the 
authorship and/or publication. 
REFERENCES 
1. Martin FA, Pop MM, Borodi G, Filip X, Kacso I. Ketoconazole salt 
and co-crystals with enhanced aqueous solubility. Cryst 
Growth Des 2013;13:4295-304. 
2. Gao Y, Gao J, Liu Z, Kan H, Zu H, Sun W, et al. Coformer selection 
based on degradation pathway of drugs: a case study of 
adefovir dipivoxil-saccharin and adefovir dipivoxil-
nicotinamide cocrystals. Int J Pharm 2012;438:327-35. 
3. Wang ZZ, Chen JM, Lu TB. Enhancing the hygroscopic stability 
of S-Oxiracetam via pharmaceutical cocrystal. Cryst Growth 
Des 2012;12:4562-6. 
4. Sanphui P, Kumar SS, Nangia A. Pharmaceutical cocrystals of 
niclosamide. Cryst Growth Des 2012;12:4588-99. 
5. Karki S, Friscic T, Fabian L, Laity PR, Day GM, Jones W. 
Improving mechanical properties of crystalline solids by 
cocrystal formation: new compressible forms of paracetamol. 
Adv Mater 2009;21:3905-9. 
6. Cheney ML, Shan N, Healey ER, Hanna M, Wojtas L, Zaworotko 
MJ, et al. Effects of crystal form on solubility and 
pharmacokinetics: a crystal engineering case study of 
lamotrigine. Cryst Growth Des 2010;10:394-405. 
7. Trask AV. An overview of pharmaceutical cocrystals as 
intellectual property. Mol Pharm 2007;4:301-9. 
8. Schultheiss N, Newman A. Pharmaceutical cocrystals and their 
physicochemical properties. Cryst Growth Des 2009;9:2950-67. 
9. Trask AV, Jones W. Crystal engineering of organic cocrystals by 
the solid-state grinding approach. Top Curr Chem 
2005;254:41-70.  
10. Lin HL, Wu TK, Lin SY. Screening and characterization of 
cocrystal formation of metaxalone with short-chain 
dicarboxylic acids induced by solvent-assisted grinding 
approach. Thermochim Acta 2014;575:313-21. 
11. Fucke K, Myz SA, Shakhtshneider TP, Boldyreva EV, Griesser UJ. 
How good are the crystallisation methods for co-crystals? A 
comparative study of piroxicam. New J Chem 2012;36:1969-77. 
12. Takata N, Shiraki K, Takano R, Hayashi Y, Terada K. Cocrystal 
screening of stanolone and mestanolone using slurry 
crystalization. Cryst Growth Des 2008;8:3032-7. 
13. Chen JM, Wang ZZ, Wu CB, Li S, Lu TB. Crystal engineering 
approach to improve the solubility of mebendazole. 
CrystEngComm 2012;14:6221-9. 
14. Berry DJ, Seaton CC, Clegg W, Harrington RW, Coles SJ, Horton 
PN, et al. Applying hot-stage microscopy to co-crystal screening: 
a study of nicotinamide with seven active pharmaceutical 
ingredients. Cryst Growth Des 2008;8:1697-712. 
15. Yamashita H, Hirakura Y, Yuda M, Teramura T, Terada K. 
Detection of cocrystal formation based on binary phase 
diagrams using thermal analysis. Pharm Res 2013;30:70-80. 
16. Moradiya H, Islam MT, Woollam GR, Slipper IJ, Halsey S, 
Snowden MJ, et al. Continuous cocrystallization for dissolution 
rate optimization of a poorly water soluble drug. Cryst Growth 
Des 2014;14:189-98.  
17. Alhalaweh A, Velaga SP. Formation of cocrystals from 
stoichiometric solutions of incongruently saturating systems 
by spray drying. Cryst Growth Des 2010;10:3302-5. 
18. Hiendrawan S, Veriansyah B, Tjandrawinata RR. Micronization 
of fenofibrate by rapid expansion of supercritical solution. J Ind 
Eng Chem 2014;20:54-60. 
19. Vieira de Melo SAB, Danh LT, Mammucari R, Foster NR. Dense 
CO2 antisolvent precipitation of levothyroxine sodium: a 
comparative study of GAS and ARISE techniques based on 
morphology and particle size distributions. J Supercrit Fluids 
2014;93:112-20. 
20. Padrela L, Rodrigues MA, Velaga SP, Matos HA, de Azevedo EG. 
Formation of indomethacin-saccharin cocrystals using 
supercritical fluids technology. Eur J Pharm Sci 2009;38:9-17. 
21. Padrela L, Rodrigues MA, Velaga SP, Fernandes AC, Matos HA, 
de Azevedo EG. Screening for pharmaceutical cocrystals using 
the supercritical fluid enhanced atomization process. J 
Supercrit Fluids 2010;53:156-64.  
22. Padrela L, Rodrigues MA, Tiago J, Velaga SP, Matos HA, de 
Azevedo EG. Tuning physicochemical properties of theophylline 
by cocrystallization using the supercritical fluid enhanced 
atomization technique. J Supercrit Fluids 2014;86:129-36. 
23. Ober CA, Gupta RB. Formation of itraconazole-succinic acid 
cocrystals by gas antisolvent cocrystallization. AAPS 
PharmSciTech 2012;13:1396-406. 
24. Ober CA, Montgomery SE, Gupta RB. Formation of 
itraconazole/l-malic acid cocrystals by gas antisolvent 
cocrystallization. Powder Technol 2013;236:122-31. 
25. Neurohr C, Revelli AL, Billot P, Marchivie M, Lecomte S, Laugier 
S, et al. Naproxen-nicotinamide cocrystals produced by CO2 
antisolvent. J Supercrit Fluids 2013;83:78-85. 
26. Mullers KC, Paisana M, Wahl MA. Simultaneous formation and 
micronization of pharmaceutical cocrystals by rapid expansion 
of supercritical solutions (RESS). Pharm Res 2015;32:702-13. 
27. Rossmann M, Braeuer A, Leipertz A, Schluecker E. Manipulating 
the size, the morphology and the polymorphism of 
acetaminophen using supercritical antisolvent (SAS) 
precipitation. J Supercrit Fluids 2013;82:230-7. 
28. Li G, Chu J, Song ES, Row KH, Lee KH, Lee YW. Crystallization of 
acetaminophen micro-particle using supercritical carbon 
dioxide. Korean J Chem Eng 2006;23:482-7. 
29. Tabernero A, del Valle EMM, Galan MA. Precipitation of 
tretinoin and acetaminophen with solution enhanced 
dispersion by supercritical fluids (SEDS). Powder Technol 
2012;217:177-88. 
30. Srirambhatla VK, Kraft A, Watt S, Powell AV. Crystal design 
approaches for the synthesis of paracetamol co-crystals. Cryst 
Growth Des 2012;12:4870-9. 
31. Andre V, Fatima M, da Piedad M, Duarte MT. Revisiting 
paracetamol in a quest for new co-crystals. CrystEngComm 
2012;14:5005-14.  
32. Sander JRG, Bucar DK, Henry RF, Baltrusaitis J, Zhang GGZ, 
Macgillivray LR. A red zwitterionic co-crystal of acetaminophen 
and 2,4-pyridinecarboxylic acid. J Pharm Sci 2010;99:3676-83.  
33. United States Pharmacopeial Convention, Inc., The United 
States Pharmacopeia. 31st ed. Rockville: United States 
Pharmacopeial Convention, Inc; 2008. 
34. Kim MS, Lee S, Park JS, Woo JS, Hwang SJ. Micronization of 
cilostazol using supercritical antisolvent (SAS) process: effect 
of process parameters. Powder Technol 2007;177:64-70. 
35. Lu E, Hornedo NR, Suryanarayanan R. A rapid thermal method 
for cocrystal screening. CrystEngComm 2008;10:665-8. 
36. Dhumal RS, Kelly AL, York P, Coates PD, Paradkar A. 
Cocrystallization and simultaneous agglomeration using hot 
melt extrusion. Pharm Res 2010;27:2725-33. 
37. Manin AN, Voronin AP, Drozd KV, Manin NG, Brandl AB, 
Perlovich GL. Cocrystal screening of hydroxybenzamides with 
benzoic acid derivatives: a comparative study of thermal and 
solution-based methods. Eur J Pharm Sci 2014;65:56-64. 
38. Mulye SP, Jamadar SA, Karekar PS, Pore YV, Dhawale SC. 
Improvement in physicochemical properties of ezetimibe using 
a crystal engineering technique. Powder Technol 
2012;222:131-8. 
39. Manin AN, Voronin AP, Manin NG, Vener MV, Shishkina AV, 
Lermontov AS. Salicylamide cocrystals: screening, crystal 
structure, sublimation thermodynamics, dissolution, and solid-
state DFT calculations. J Phys Chem B 2014;118:6803-14. 
40. Garekani HA, Ford JL, Rubinstein MH, Siahboomi ARR. 
Formation and compression characteristics of prismatic 
polyhedral and thin plate-like crystals of paracetamol. Int J 
Pharm 1999;187:77-89. 
41. Chadha R, Saini A, Jain DS, Venugopalan P. Preparation and solid-
state characterization of three novel multicomponent solid forms 
of oxcarbazepine: improvement in solubility through saccharin 
cocrystal. Cryst Growth Des 2012;12:4211-24. 
42. Moynihan HA, Hare IPO. Spectroscopic characterisation of the 
monoclinic and orthorhombic forms of paracetamol. Int J 
Pharm 2002;247:179-85. 
Tjandrawinata et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 2, 89-98 
98 
43. Wang L, Tan B, Zhang H, Deng Z. Pharmaceutical cocrystals of 
diflunisal with nicotinamide or isonicotinamide. Org Process 
Res Dev 2013;17:1413-8. 
44. Chow SF, Chen M, Shi L, Chow AHL, Sun CC. Simultaneously 
improving the mechanical properties, dissolution performance, 
and hygroscopicity of ibuprofen and flurbiprofen by 
cocrystallization with nicotinamide. Pharm Res 2012;29:1854-65. 
45. Brittain HG. Vibrational spectroscopic studies of cocrystals and 
salts.3. cocrystal products formed by benzenecarboxylic acids 
and their sodium salts. Cryst Growth Des 2010;10:1990-2003.  
46. Kaialy W, Larhrib H, Chikwanha B, Shojaee S, Nokhodchi A. An 
approach to engineer paracetamol crystals by antisolvent 
crystallization technique in presence of various additives for 
direct compression. Int J Pharm 2014;464:53-64. 
47. Renuka, Singh SK, Gulati M, Kaur I. Characterization of solid 
state forms of glipizide. Powder Technol 2014;264:365-76. 
48. Rossmann M, Braeuer A, Dowy S, Gallinger TG, Leipertz A, 
Schluecker E. Solute solubility as criterion for the appearance of 
amorphous particle precipitation or crystallization in the 
supercritical antisolvent (SAS) process. J Supercrit Fluids 
2012;66:350-8. 
49. Perumalla SR, Shi L, Sun CC. Ionized form of acetaminophen 
with improved compaction properties. Cryst Eng Comm 
2012;14:2389-90. 
50. Chattoraj S, Shi L, Chen M, Alhalaweh A, Velaga S, Sun CC. Origin 
of deteriorated crystal plasticity and compaction properties of 
a 1:1 cocrystal between piroxicam and saccharin. Cryst Growth 
Des 2014;14:3864-74. 
51. Sun C, Grant DJW. Effects of initial particle size on the tableting 
properties of L-lysine monohydrochloride dihydrate powder. 
Int J Pharm 2001;251:221-8. 
52. Garekani HA, Sadeghi F, Badiee A, Mostafa SA, Siahboomi ARR. 
Crystal habit modifications of ibuprofen and their 
physicomechanical characteristics. Drug Dev Ind Pharm 
2001;27:803-9.  
53. Nokhodchi A, Bolourtchian N, Dinarvand R. Crystal 
modification of phenytoin using different solvents and 
crystallization conditions. Int J Pharm 2003;250:85-97. 
54. Aher S, Dhumal R, Mahadik K, Ketolainen J, Paradkar A. Effect 
of cocrystallization techniques on compressional properties of 
caffeine/oxalic acid 2:1 cocrystal. Pharm Dev Technol 
2013;18:55-60. 
55. Rasenack N, Muller BW. Crystal habit and tableting behavior. 
Int J Pharm 2002;244:45-57. 
56. Hiendrawan S, Veriansyah B, Tjandrawinata RR. A bottom-up 
process approach for micronization of ibuprofen. J Chem 
Pharm Res 2015;7:708-15. 
 
